U.S. FDA Acknowledges Receipt of Evofem Biosciences’ New Drug Application Resubmission for Amphora for the Prevention of Pregnancy

SAN DIEGO, Dec. 18, 2019 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) acknowledged receipt of the New Drug…Original Article